Julie VanOrsdel Daves
Keine laufenden Positionen mehr
Vermögen: - $ am 30.04.2024
Profil
Julie VanOrsdel Daves worked as a Senior Director-Clinical Operations at miRagen Therapeutics, Inc. from 2016 to 2018.
Prior to that, she was the Global Head & Senior Director-Clinical at Chiltern International, Inc. from 2015 to 2016.
From 2007 to 2011, she held the position of Senior Manager-Clinical Development at BioCryst Pharmaceuticals, Inc. In 2021, she served as the Vice President & Global Head-Clinical Operations at Sanifit Therapeutics SA. From 2018 to 2021, she worked as the Vice President-Outsourcing & Vendor Management at Edgewise Therapeutics, Inc. Currently, she is the Senior VP-Clinical Development Operations at DiaMedica Therapeutics, Inc. Ms. Daves completed her undergraduate degree at North Carolina State University and her graduate degree at George Washington University School of Medicine & Health.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 25.03.2024 | 0 ( -.--% ) | - $ | 30.04.2024 |
Ehemalige bekannte Positionen von Julie VanOrsdel Daves
| Unternehmen | Position | Ende |
|---|---|---|
| DIAMEDICA THERAPEUTICS INC. | Corporate Officer/Principal | 18.04.2024 |
Sanifit Therapeutics SA
 Sanifit Therapeutics SA BiotechnologyHealth Technology Sanifit Therapeutics SA develops pharmaceuticals for calcification disorders. Its pipeline consists of treatments for calcification disorders, such as calciphylaxis and osteoporosis. The company was founded by Felix Grases in 2004 and is headquartered in Palma de Mallorca, Spain. | Corporate Officer/Principal | 01.08.2022 |
| EDGEWISE THERAPEUTICS, INC. | Corporate Officer/Principal | 01.08.2021 |
miRagen Therapeutics, Inc. /Old/
 miRagen Therapeutics, Inc. /Old/ Pharmaceuticals: MajorHealth Technology miRagen Therapeutics, Inc. develops microRNA-based therapeutics for cardiovascular and muscle diseases. It leverages in-house expertise in miRNA biology, oligonucleotide chemistry, and drug development to evaluate and advance RNA-based technologies and potential drug candidates for its own pipeline and in strategic collaborations. The firm aso focuses on hematological malignancies, fibrosis and neuro inflammation. The company was founded by William S. Marshall, Michael R. Bristow, Marvin H. Caruthers, Bruce Lee Booth and Eric Newell Olson in 2007 and is headquartered in Boulder, CO. | Corporate Officer/Principal | 01.02.2018 |
Chiltern International, Inc.
 Chiltern International, Inc. BiotechnologyHealth Technology Part of Laboratory Corp. of America Holdings, Chiltern International, Inc. is a contract research organization that offers clinical development, scientific services, and collaborative technologies. | Corporate Officer/Principal | 01.02.2016 |
Ausbildung von Julie VanOrsdel Daves
| North Carolina State University | Undergraduate Degree |
| George Washington University School of Medicine & Health | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| DIAMEDICA THERAPEUTICS INC. | Health Technology |
| EDGEWISE THERAPEUTICS, INC. | Health Technology |
| BIOCRYST PHARMACEUTICALS, INC. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Sanifit Therapeutics SA
Sanifit Therapeutics SA BiotechnologyHealth Technology Sanifit Therapeutics SA develops pharmaceuticals for calcification disorders. Its pipeline consists of treatments for calcification disorders, such as calciphylaxis and osteoporosis. The company was founded by Felix Grases in 2004 and is headquartered in Palma de Mallorca, Spain. | Health Technology |
miRagen Therapeutics, Inc. /Old/
miRagen Therapeutics, Inc. /Old/ Pharmaceuticals: MajorHealth Technology miRagen Therapeutics, Inc. develops microRNA-based therapeutics for cardiovascular and muscle diseases. It leverages in-house expertise in miRNA biology, oligonucleotide chemistry, and drug development to evaluate and advance RNA-based technologies and potential drug candidates for its own pipeline and in strategic collaborations. The firm aso focuses on hematological malignancies, fibrosis and neuro inflammation. The company was founded by William S. Marshall, Michael R. Bristow, Marvin H. Caruthers, Bruce Lee Booth and Eric Newell Olson in 2007 and is headquartered in Boulder, CO. | Health Technology |
Chiltern International, Inc.
Chiltern International, Inc. BiotechnologyHealth Technology Part of Laboratory Corp. of America Holdings, Chiltern International, Inc. is a contract research organization that offers clinical development, scientific services, and collaborative technologies. | Health Technology |
